SM
HZNP

SG3 Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

SG3 Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,600
Closed -$1.78M – 197
2022
Q4 		$1.78M Buy
+15,600
New +$1.3M 0.26% 60

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SG3 Management's HZNP Position: Q1 2017 in Review

SG3 Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2017, closing a stake of 10,000 shares — an estimated $162K sold.

SG3 Management first reported a position in HZNP in Q4 2016 and held it in 1 quarter. The position peaked at $162K in Q4 2016. 210 funds tracked by Wall St. Rank hold HZNP as of Q1 2017.

  • SG3 Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2017 after selling out during the quarter.
  • SG3 Management sold 10,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2017, an estimated $162K.
  • SG3 Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016 and held it in 1 quarter.
  • SG3 Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $162K in Q4 2016.
  • 210 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2017.

Based on SG3 Management's 13F filing for Q1 2017, filed 25 Jan 2018.